- Home
- HMR vs HLVX Comparison
HMR vs HLVX Comparison
Compare HMR & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMR
- HLVX
- Stock Information
- Founded
- HMR 1984
- HLVX 2020
- Country
- HMR Greece
- HLVX United States
- Employees
- HMR N/A
- HLVX N/A
- Industry
- HMR Marine Transportation
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- HMR Consumer Discretionary
- HLVX Health Care
- Exchange
- HMR Nasdaq
- HLVX Nasdaq
- Market Cap
- HMR 87.9M
- HLVX 104.3M
- IPO Year
- HMR N/A
- HLVX 2022
- Fundamental
- Price
- HMR $1.44
- HLVX $2.09
- Analyst Decision
- HMR Strong Buy
- HLVX Hold
- Analyst Count
- HMR 2
- HLVX 1
- Target Price
- HMR $6.00
- HLVX $2.00
- AVG Volume (30 Days)
- HMR 73.6K
- HLVX 1.2M
- Earning Date
- HMR 08-11-2025
- HLVX 08-06-2025
- Dividend Yield
- HMR N/A
- HLVX N/A
- EPS Growth
- HMR N/A
- HLVX N/A
- EPS
- HMR N/A
- HLVX N/A
- Revenue
- HMR $27,657,887.00
- HLVX N/A
- Revenue This Year
- HMR $36.04
- HLVX N/A
- Revenue Next Year
- HMR $35.83
- HLVX N/A
- P/E Ratio
- HMR N/A
- HLVX N/A
- Revenue Growth
- HMR N/A
- HLVX N/A
- 52 Week Low
- HMR $1.40
- HLVX $1.34
- 52 Week High
- HMR $10.04
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- HMR N/A
- HLVX 53.75
- Support Level
- HMR N/A
- HLVX $2.07
- Resistance Level
- HMR N/A
- HLVX $2.13
- Average True Range (ATR)
- HMR 0.00
- HLVX 0.03
- MACD
- HMR 0.00
- HLVX 0.00
- Stochastic Oscillator
- HMR 0.00
- HLVX 50.00
About HMR Heidmar Maritime Holdings Corp. Common Stock
Heidmar Maritime Holdings Corp is an asset-light tanker pool, and commercial and technical management company. The company is a fast-growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. The company has also recently expanded its business to offer pool management of dry bulk vessels and technical management. The company generates maximum revenue from Singapore.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.